Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards



    - E. coli O157:H7 vaccine named "best new veterinary product for
    livestock" -

    BELLEVILLE, ON, Sept. 27 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC),
a research-based, technology-driven Canadian biopharmaceutical company, today
announced that its vaccine against E. coli O157:H7 in cattle has been
recognized internationally as the best new veterinary product for livestock.
The Company received the Animal Pharm industry excellence award at the Animal
Pharm Awards '07 dinner this week in London, UK. Animal Pharm is a worldwide
business-to-business news service for the animal health industries, published
by Informa Healthcare, part of the Informa Group. The Animal Pharm newsletter
has been published for more than 20 years and has more than 2,000 readers in
animal health companies and related businesses around the world
(www.animalpharmnews.com or www.animalpharmawards.com ).
    The "best new veterinary product for livestock" award recognizes
excellence in pharmaceutical or vaccine development for production animals. In
this category, the 12-member panel of independent industry judges looks for
the product that represents the greatest therapeutic, prophylactic, or
production advance. The shortlist of nominees for this award included Merial
SAS, Norbrook Laboratories Ltd. and Schering-Plough Animal Health.
    "This international recognition of our E. coli O157:H7 vaccine provides
external validation of its importance and sophistication by our peers in the
animal health industry," said Graeme McRae, President & CEO of Bioniche Life
Sciences Inc. "This made-in-Canada technology has taken seven years of
development and many millions of dollars in investment. It represents the
first vaccine for intervention against this dangerous bacterium and we are
proud to provide this vaccine to the marketplace."
    The vaccine remains under review by The Canadian Food Inspection Agency
(CFIA) and The United States Department of Agriculture (USDA). It is important
to recognize that there is no precedent for a vaccine against a zoonotic agent
(disease that transmits from animals to humans) where the animal is not made
ill. In the course of its review process, the CFIA approved distribution of
the vaccine under its Permit to Release Veterinary Biologics regulations. This
is equivalent to a conditional license in the U.S. These regulations allow
cattle owners, through their veterinarians, to request vaccine be supplied to
them by Bioniche.
    Since that time, Bioniche has commenced production of the E. coli O157:H7
cattle vaccine at its Belleville, Ontario facility. This supply is now being
provided to veterinarians requesting vaccine under the Canadian Permit to
Release regulations. Bioniche will continue to scale up as full domestic and
international approvals are received. Until such approvals are received, all
vaccine will be shipped to Canadian veterinarians as permit requests are
received and approved by the CFIA.
    In order to progress from shipping under permits to a full license, the
CFIA indicated that Bioniche was required to provide additional data
confirming reduction in E. coli O157:H7 shedding by vaccinated animals. This
information was provided to the CFIA in the spring and is currently under
review.

    About E. coli O157:H7

    Escherichia coli (E. coli) bacteria are normal organisms found in the
intestinal tract of all animals and humans. Most E. coli are non-pathogenic
(non-disease-causing) to their host, however certain strains can cause
intestinal disease and, occasionally, other significant systemic disease. The
E. coli O157:H7 bacterium, which was first identified in South America in the
late 1970s and drifted northward, produces a powerful toxin (shiga/vero toxin)
that can cause severe illness in humans and often result from consumption of
contaminated food or water. Today, the bacteria can be found in most cattle
herds in North America, South America, Europe and Asia. Ruminant livestock
(e.g. cattle) are considered the major reservoir of E. coli O157:H7 worldwide.
Numerous studies have demonstrated that the incidence of E. coli O157:H7 in
beef and dairy cattle is widespread and that the organism is found in, on, and
around cattle in all parts of the world. Use of manure as fertilizer for crop
production and run-off from beef and dairy cattle operations are a source of
contamination for the general environment, as well as surface and ground
water. E. coli O157:H7 contamination of food and water as a result of fecal
shedding by livestock is a well-recognized and documented threat to human
health, with approximately 100,000 North Americans made ill by it each year.
For more information, please visit www.fightecoli.com.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
195 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159E




For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890